JPRN-UMIN000046985已完成未知
Research of Tolvaptan prescription in SIADH patients (Observational research using DPC) - Research of Tolvaptan prescription in SIADH patients
Otsuka Pharmaceutical Co., Ltd. Medical Affairs Department0 个研究点目标入组 2,800 人开始时间: 2022年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 2,800
研究概览
简要总结
As a result of examination using actual clinical data using the DPC database, half of the tolvaptan starting dose to SIADH was started from a low dose (3.75 mg), and the average administration period was 32.7 days for 3.75 mg and 33.1 days for 7.5 mg. Since mean of the serum sodium concentration at the start of the tolvaptan-administered case was 120.30 mEq / L, it is considered that the appropriate starting dose was selected for administration.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •- Patients under 18 years old
研究者
相似试验
已完成
3 期
Tolvaptan SIADH StudyJPRN-jRCT2080223457Otsuka Pharmaceutical Co., LTD.16
尚未招募
不适用
A study of Tolvaptan to investigate the pharmacokinetics and diuretic effectcongestive heart failureJPRN-UMIN000006726Kanagawa Children's Medical Center10
已完成
1 期
AiDing Diuresis wIth Tolvaptan (ADD-IT)CardiomyopathyCongestive Heart FailureNCT02646540Emory University14
已完成
3 期
A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADHSyndrome of Inappropriate Antidiuretic Hormone SecretionNCT03048747Otsuka Pharmaceutical Co., Ltd.16
已完成
不适用
Randomized controlled trial of tolvaptan and carperitide to fluid retention in patients with congestive heart failureAcute congestive heart failure (including acute exacerbation of chronic heart failure) patietntsJPRN-UMIN000006258Fukushima Medical University100
